Multiple Chromoananasynthesis in a Rare Case of Sporadic Renal Leiomyosarcoma: A Case Report

Kirill Igorevich Anoshkin1*, Kristina Olegovna Karandasheva1, Kristina Mikhailovna Goryacheva2, Denis Valer’evich Pyankov3, Philipp Aleksandrovich Koshkin3, Tatiana Vladimirovna Pavlova4, Alexandr Nikolayevich Bobin4, Evgeniy Valer’yevich Shpot2, Yaroslav Nikolayevich Chernov2, Andrei Zinov’yevich Vinarov2, Dmitry Vladimirovich Zaletaev2, Sergei Ivanovich Kutsev1 and Vladimir Viktorovich Strelnikov1

1 Research Centre for Medical Genetics, Moscow, Russia, 2 I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 3 Genomed Ltd., Moscow, Russia, 4 N.N. Burdenko Main Military and Clinical Hospital, Moscow, Russia

We present the genetic profile of kidney giant leiomyosarcoma characterized by sequencing of 409 cancer related genes and chromosomal microarray analysis. Renal leiomyosarcomas are extremely rare neoplasms with aggressive behavior and poor survival prognosis. Most frequent somatic events in leiomyosarcomas are mutations in the TP53, RB1, ATRX, and PTEN genes, chromosomal instability (CIN) and chromoanagenesis. 67-year-old woman presented with a right kidney completely replaced by tumor. Immunohistochemical reaction on surgical material was positive to desmin and smooth muscle actin. Molecular genetic analysis revealed that tumor harbored monosomy of chromosomes 3 and 11, gain of Xp (ATRX) arm and three chromoananasynthesis regions (6q21-q27, 7p22.3-p12.1, and 12q13.11-q21.2), with MDM2 and CDK4 oncogenes copy number gains, whereas no copy number variations (CNVs) or tumor specific single nucleotide variants (SNVs) in TP53, RB1, and PTEN genes were present. We hypothesize that chromoananasynthesis in 12q13.11-q21.2 could be a trigger of observed CIN in this tumor.

Keywords: leiomyosarcoma, renal, chromoanagenesis, chromoananasynthesis, MDM2, microarray, NGS, chromosomal instability

INTRODUCTION

Leiomyosarcomas (LMSs) of the kidney are very rare renal tumors that account for 0.12% of all renal malignancies (1). Most often leiomyosarcomas of the kidney are found in females with a mean age of 50–60 years and have poor survival prognosis (1, 2). Despite the high representation among renal sarcomas (50–60%), the information about LMS in the kidney is limited. Most commonly renal LMSs originate from smooth muscles of kidney veins, but can also arise from renal capsule, renal pelvis, blood vessels, and calyxes (3).
Current studies, focused on the genetic profiling of LMS aggregate tumors from different localizations (lower extremity, trunk, uterus, or retroperitoneum) where in the latter case, specific locations of the tumor are not specified (4–7). Leiomyosarcomas of any location predominantly have mutations in TP53, RB1, ATRX, and PTEN or copy number changes involving these genes and also harbor multiple chromosomal rearrangements including chromoanagenesis (8).

As far as we know, the single research was published, in which authors aimed to study the cytogenetic profile of renal LMS, and showed hypotetraploid karyotype in tumor material (9). Yet, there are no published studies with more extensive genetic approach on leiomyosarcoma of the kidney. Here we present a rare case of leiomyosarcoma of the right kidney with radiographic findings, microscopic and immunohistochemical examination, molecular genetic profiling of 409 tumor related genes and chromosomal microarray analysis.

**CASE PRESENTATION**

A 67-year-old woman with enlarged abdomen, dull pain in the lumbar region on the right, palpitation and moderate weakness was admitted to the Urological clinic department of I.M. Sechenov First Moscow State Medical University in July 2014. The patient reported no relevant clinical family history. The patient signed informed agreement to undergo diagnostic procedures and treatment, as well as to participate in the study, and for the presentation of clinical and molecular data in scientific and medical literature. This case report was approved by the local Ethics Committee at the Research Centre for Medical Genetics, Moscow, Russia.

The patient underwent an ultrasonic examination that revealed a mass in the right kidney with a size of 176 × 164 mm. Multi-slice spiral computed tomography showed that right kidney was displaced upward, rotated anteriorly because of spherical soft tissue mass in the middle and lower segments of the kidney with a size 206 × 186 × 188 mm and clear contours in the structure of which arterial vessels were determined (Figure 1A). Lesion extended into the sinus of the right kidney, ingrew in ureter at the ureteropelvic junction and more distal and encircled pelvis. Lesion also lied tightly next to psoas major muscle and inferior vena cava. The pyelocalkical system of the right kidney was expanded: a calyx and a pelvis were 30 mm and 45 × 28 mm in size, respectively. The mass unevenly accumulated a contrast agent. Excretion of the contrast agent by the right kidney was absent.

**Treatment**

Based on the obtained diagnostic data, the multidisciplinary board was held, implying the participation of surgical oncologist, oncologist, pathomorphologist, a specialist in radiation diagnostics and urologist. The nephrectomy of the right kidney and regional lymphadenectomy was performed. During the operation, it was noted that the inferior vena cava from the adrenal gland to aortic bifurcation is involved in the tumor process. The invasion into the liver was not observed. The resected tumor had a size of 300 × 253 × 150 mm and 4 kg of weight (Figure 1B). Incision shows that the right kidney was completely replaced by tumor mass (Figure 1C).

**Outcome**

Despite the successful surgery, the follow up was not possible by the reason of patient’s death in post-operative period. The cause of death was not related to nephrectomy.

**Microscopy and Immunohistochemistry**

The microscopic examination of the tumor revealed pleomorphic bundles of spindle-shaped cells with large hyperchromatic nuclei, among which multinucleated cells were found. High mitotic activity (17 mitoses per 10 fields with magnification ×400) and foci of necrosis were observed (Figure 1D). The immunohistochemistry showed positive reaction for smooth muscle actin (Figure 1E) and desmin (Figure 1F) and negative reaction for CD99, CD43, CD117, S-100, MCK/PCK, and DOG-1. Taking into account the histological and immunohistochemical data, the changes correspond to Grade 3 kidney leiomyosarcoma (overall score of 6 points: tumor differentiation, 3; mitotic activity, 2; necrosis, 1) according to FNCLCC gradation of soft tissue tumors (10).

**MATERIALS AND METHODS**

**DNA Extraction**

DNA was extracted from the formalin-fixed, paraffin-embedded tumor tissue by using GeneRead DNA FFPE kit (Qiagen, Germany), and from whole peripheral blood using standard phenol-chloroform extraction protocol.

**DNA Sequencing**

DNA sequencing was performed using Ion AmpliSeq targeted amplification technology and AmpliSeq Comprehensive Cancer Panel (Thermo Fisher Scientific, United States). The cancer-specific primer panel provides exon coverage of 409 oncogenes and tumor suppressor genes.

**Bioinformatic Analysis**

The bioinformatic workflow for sequencing data analysis was based on Torrent Suite software (version 5.10.1). CNVs were estimated using the ONCOCNV (11) package (version 6.9).

**Chromosomal Microarray Analysis**

For the detection of chromosomal aberrations, we used an SNP-array CytoScan HD (Thermo Fisher Scientific, United States) on GeneChip Scanner 3000 7G System (Applied Biosystems, United States) following the manufacturer’s recommendations. Data were analyzed with Chromosome Analysis Suite software (Affymetrix). All copy number alterations were manually reviewed. To detect and discern chromoanagenesis we used criteria that were previously described (12–14): more than five breakpoints with clustered distribution of the
segments with normal copy number interspersed with copy number gains.

RESULTS

Next Generation Sequencing

Next generation sequencing was performed on gDNA of whole blood and FFPE tumor tissue sample. Median of read coverage in tumor and blood samples was 393× and 371×, respectively. No mutations associated with any genetic syndrome were found. We did not find any pathogenic SNVs in the most commonly mutated in LMS genes TP53, RB1, ATRX, and PTEN, as well as in less commonly mutated, ATM and EGFR2 (15). Several SNVs previously reported for LMS (7) in the KLF6 (NC_000010.10:g3824388_3824389insG), WAS (NC_000023.10:g.48547111_48547112insC), AKT1 (NC_000014.8:g.105238770_105238771insC), and GPR124 (NC_000008.10:g.37692704G>A) genes were also present in our sample, but we have observed low frequency of alternative alleles and sequencing strand bias for these variants. We have also revealed these SNVs in other samples that were analyzed in our laboratory, also with low frequency of alternative allele and with strand bias. Since we used the same targeted amplification and sequencing technology and the same cancer-specific primer panel (AmpliSeq Comprehensive Cancer Panel, Thermo Fisher
Scientific, United States) as in work of Rao et al. (7), we suggest that these SNVs are merely sequencing artifacts.

**Chromosomal Microarray Analysis**

By using chromosomal microarray analysis (CMA), we have revealed numerous chromosomal aberrations in the tumor sample. The tumor carried a vast number of gains and losses of fractions of chromosomes, and also monosomy of chromosomes 3 and 11 (Figure 2A and Supplementary Figures 1, 2A,B).

[FIGURE 2 | Copy number alterations in whole genome view summary and regions with chromoanasynthesis presented by weighted Log2 Ratio, allele difference, B-Allele Frequency (BAF) and smooth signal. (A) Whole Genome View summary. (B) Chromoanasynthesis in 6q21-q27 region that harbors 13 oncogenes including MYB. (C) Chromoanasynthesis in 7p22.3-p12.1 region that harbors 10 oncogenes including MACC1. (D) Chromoanasynthesis in 12q13.11-q21.2 region that harbors nine oncogenes including MDM2 and CDK4 in q13.3 and q15 bands, respectively.

which in complex refers to chromosomal instability (CIN). Gains were seen in 1p22.2-p21.3, 2p25.3-p24.3, 3q28-q29, 4p16.3-p13, 4q34.2-q34.3, 9p24.3-p23, 10p15.3-p15.2, 11p15.4, 17q12-q25.3, 19p13.3, 22q12.1-q13.1, and Xq. Heterozygous losses were observed in 1q43-q44, 7q35, 10p15.3, 10p15.1-p12.1, 15q, 16q, 17q25.3, 18q23, 19q, 22q12.1, 22q13.2-q13.33, and Xp (Figure 2A and Supplementary Figure 1). These results were generally confirmed by ONCOCNV analysis of the NGS data (Supplementary Figure 3). Fifteen short regions of homozygous losses varying from 8 nucleotides to 136 kilobases were identified (Supplementary Table 1). Two regions with homozygous losses affected genes *PTCHD3* [arr(GRCh37)p12.1(27625952_27688513)x0)] and *IL3RA* [arr(GRCh37)Xp22.33(1459624_1460944)x0] in 3′ UTR and 5′ UTR, respectively. We did not observe copy number variations in regions that harbor *PTEN*, *TP53*, or *RB1* genes, but gain of Xq arm where *ATRX* (Xq21.1) gene is located was observed (Supplementary Figure 4).

In addition, we discovered three regions (6q21-q27, 7p22.3-p12.1, and 12q13.11-q21.2) with at least 13 switches alternating different copy gains with normal copy state that refers to chromoanasynthesis (Figures 2B–D). These regions harbor 31 oncogenes (Table 1) according to ONGene database (16) among which are *MYB* and *FYN* in 6q region (Figure 2B), *MACC* in 7p region (Figure 2C), *MDM2* and cyclin dependent kinase 4 (*CDK4*) (Figure 2B and Supplementary Figures 5A,B) in 12q region. Analysis of the location of breakpoints in chromoanasynthesis has revealed that in total 60 genes, including 2 oncogenes (*GLI3, HMG2*), 6 tumor suppressor genes (17) and *SPI* transcription factor gene were found to be truncated by chromoanasynthesis (Table 1).

**DISCUSSION**

Here we report a rare case of leiomyosarcoma of the kidney with multiple chromoanasynthesis and monosomy of 3 and 11 chromosomes. According to recent studies, LMSs of any location are known to be tumors hallmarks of which are various types of mutations in *TP53* (17p13), *RB1* (13q14), *PTEN* (10q23), or *ATRX* (Xq21.1) genes (4–6, 15, 18, 19). SNVs are the most common types of mutation occurring in 71% in LMSs (4), but in the case presented here, DNA sequencing of 409 tumor related genes did not reveal any pathogenic SNVs in *TP53*, *RB1*, *PTEN*, and *ATRX* or any other of the analyzed genes. Few shared SNVs observed by Rao et al. (7) were also revealed in our case, however, our in-house database classifies them as sequencing artifacts intrinsic for the sequencing method used.

By using CMA we found that tumor harbored a vast amount of copy number aberrations (>20) including monosomy of 3 and 11 chromosomes, which are signs of CIN (20–22) (Figure 2A and Supplementary Figures 1, 2A,B, 3). Previously cytogenetic research of leiomyosarcomas revealed that there is a correlation between the quantity of changes and size of tumors (23). It was noticed that tumors larger than 5 cm had a mean of copy number changes of 13 (23). Additionally, gains of 1q, 5p, 6q, and 8q were also correlated with larger tumors (23). Abundance of CNVs...
in leiomyosarcoma (24–26) (Figure 2A and Supplementary Figures 5A,B) (37, 43). However, Cortés-Ciriano et al. (8) showed that chromoanogenesis is a replication-based mechanism, either microhomology-mediated break-induced replication (MMBIR), or serial fork stalling and template switching (FoStE5) (14). In these models, lagging DNA strand serially disengages and is held by another nearby template; a series of microhomology-dependent template and switching events occur resulting in chromoanogenesis (39).

Several studies show that such replication-based models may occur in micronuclei (40–42). Crasta et al. (40) performed an experiment which showed that p53 knockout results in an increasing number of micronuclei with evidence of double strand breaks in them. It was also demonstrated that fragmentation and subsequent assembly of chromatids localized in micronuclei can initiate MMBIR process (41). Research shows that disruption of p53 pathway, primarily in TP53 gene, are associated with chromoanogenesis in pediatric cancers, and can be a trigger for CIN and numerical or structural aneuploidies (37, 43). However, Cortés-Ciriano et al. (8) showed that only 38% samples with inactivating TP53 mutations demonstrate chromoanogenesis, whereas 60% of samples with chromoanogenesis show no mutation in TP53 nor MDM2 amplification. In our case chromoanogenesis in 12q region affects MDM2 oncogene and CDK4, with their fourfold copy number increase (Supplementary Figures 5A,B). These genes play key roles in cell cycle and are often co-amplified in sarcomas. They are also targets that are approved or clinically observed in our sample, as well as 1q and 6q gains, support this observation. With regards to the correlation of tumor size and copy gains, chromoanogenesis discovered in 6q arm that harbors 13 oncogenes including MYB, could also theoretically correlate with large size of the tumor (Figure 2B). MYB had previously been suggested a likely candidate oncogene involved in LMS pathogenesis (23). We have also observed monosomy of 3 and 11 chromosomes, which is not a common event in leiomyosarcoma (24–26) (Figure 2A and Supplementary Figures 1, 2A,B, 3). Studies report that karyotypes in LMS are not stable and harbor various and numerous CNVs (4, 5, 21, 23). Aberrations in leiomyosarcomas mostly occur in regions 17p13, 13q14, 10q23, affecting TP53, RB1, and PTEN genes; however, other less recurrent aberration were also found (4, 5, 23). Aberration in our sample did not occur in bands 17p13, 13q14, 10q23, whereas gain was detected in the long arm of the X chromosome, where the ATRX (q21.1) gene is located (Figure 2A and Supplementary Figure 4).

Additionally, with CMA we have determined three regions with chromoanogenesis, which is one type of chromoanagenesis (Figures 2B–D). Chromoanogenesis is a massive complex of genomic and chromosomal aberrations characterized by tens to hundreds of simultaneously locally clustered DNA rearrangements, in which from one to multiple chromosomes can be involved (14, 27). Chromoanogenesis is considered to be a rare (5%) but crucial event in the pathogenesis of cancer (8, 28). However, in a recent research conducted by Cortés-Ciriano et al. (8) chromoanogenesis (chromothripsis) was identified in 29% of analyzed cancer samples, although the frequency varied markedly across cancer types, with more than 50% in soft tissue sarcomas and leiomyosarcomas (8).

Chromoanogenesis groups three major distinct phenomena: chromothripsis, chromoanogenesis, and chromosome and other rare chromothripsis-like events (14, 27, 29, 30). The first discovered chromoanogenesis event was chromothripsis (chromas – chromosome and thripsis – shattering into pieces) described by Stephens et al. (31), which is often used nowadays to describe all types of such phenomenon (8, 32). With respect to the term and to authors using it, we will use chromoanogenesis instead of chromothripsis to further combine these phenomena. Rearrangements that are caused by chromoanogenesis can impact genome in various ways, such as pathogenic gene fusion, truncation of haploinsufficient or tumor suppressor genes in breakpoints, or the formation of double minute chromosomes containing oncogenes that might gain increased expression through an increase in the number of their copies (12, 14, 33–37).

The key difference between chromoanogenesis and chromothripsis is that chromoanogenesis harbors copy gains in addition to losses, whereas chromothripsis has almost complete absence of gains (14, 38). Typically, chromoanogenesis occurs in one or few chromosomes (12–14). It is proposed that the cause of chromoanogenesis is a replication-based mechanism, either microhomology-mediated break-induced replication (MMBIR), or serial fork stalling and template switching (FoStE5) (14). In these models, lagging DNA strand serially disengages and goes to another nearby template; a series of microhomology-dependent template and switching events occur resulting in chromoanogenesis (39).

### Table 1

| Chromoanogenesis in region | 6q21-q27 | 7p22.3-p12.1 | 12q13.11-q21.2 |
|---------------------------|---------|-------------|---------------|
| Amplified oncogenes       | MAS1, AH11, GRM1, SGK1, MYB, CCDC28A, CENPW, FYN, ECT2L, WTA, PBOV1, LUAD1T1, CTGF | CARD11, GNA12, HOXA1, HOXA9, HOXA12, AS2, INTS1, MACC1, RAC1, TWIST1, MAFK | MDM2, CDK4, DCD, HMGA2, AGAP2, LETMD1, YEATS4, ERBB3 |
| Oncogenes                 | FOXO3, IGF2R, PPARG, PLAQL1 | GLI3, SFRP4, POU6F2 | HMGA2 |
| Tumor suppressor genes    | EPM2A, RMDN1, UNC93A, TOP10L2, CCDC170, DACT2, EPB41L2, FAM120B, PHACTR2,PSMB1 | NPSR1, EPDR1, TNS3, HOXA11, NPSR1-AS1, GPR141, ELMO1, TRA2A, BB59, DPY19L1P1, AVL9, FAM221A, UNC01162, HOXA13, OAMK2B, SEPT7P2, STK31, YAE1D1 | KRT4, RPSAP52, PDCE1B, ZDHHC17, WIBG, SP1, SMUG1, SCN8A, RAP1B, R3HDM2, PTPRO, PTPR8, BSBPL8, OS9, ORECP7P, NAV3, MDM1, KRT86, KRRT3, KRT7, KRT121P, GILPR1L1, FAN1M2A2, CAPS2 |
| Other genes               | EPM2A, RMDN1, UNC93A, TOP10L2, CCDC170, DACT2, EPB41L2, FAM120B, PHACTR2,PSMB1 | NPSR1, EPDR1, TNS3, HOXA11, NPSR1-AS1, GPR141, ELMO1, TRA2A, BB59, DPY19L1P1, AVL9, FAM221A, UNC01162, HOXA13, OAMK2B, SEPT7P2, STK31, YAE1D1 | KRT4, RPSAP52, PDCE1B, ZDHHC17, WIBG, SP1, SMUG1, SCN8A, RAP1B, R3HDM2, PTPRO, PTPR8, BSBPL8, OS9, ORECP7P, NAV3, MDM1, KRT86, KRRT3, KRT7, KRT121P, GILPR1L1, FAN1M2A2, CAPS2 |

**Funding Information**

This study was funded by the Ministry of Science and Higher Education, Poland (grant no. UMO-2019/33/B/NZ6/03125).
tested for therapy (44). Furgason et al. (45) and Garsed et al. (46) in their studies suggest that it is very likely that chromoanagenesis occurring in chromosome 12q region, that harbors MDM2 and CDK4, cause the derivation of double minute chromosomes through disruption of p53 pathway.

We have also found that chromoanagenesis in 6q21q27 region harbors MYB oncogene (Figure 2B). MYB oncogene is involved in the regulation of cell proliferation, differentiation and apoptosis (47). Highly expressed MYB was shown in leukemias, hereditary BRCA1 breast cancer and colon cancer (47–50).

In the 7p arm chromoanagenesis region, we detected MACC1 gene gain (Figure 2C). Metastasis associated in colon cancer 1 (MACC1) is an oncogene that regulates HGF/c-Met pathway that is known to play significant role in carcinogenesis by suppressing apoptosis and facilitating migration and invasion of cancer cells (51). MACC1 overexpression results in promotion of cell proliferation (52).

We have described a spectrum of molecular genetic alterations in a rare case of giant renal leiomyosarcoma, among which chromoanagenesis in 12q13.11-q21.2 which harbor crucial genes that are involved in cell cycle, MDM2 and CDK4, may be speculated to trigger CIN events including chromoanagenesis in 6q21-q27 and 7p22.3-p12.1. Involvement of p53 pathway deregulation in the development of such massive chromosomal aberrations has been described in multiple studies (8, 37, 40, 41, 43, 45, 46, 53). As for chromoanagenesis in 12q13.11-q21.2 itself, it could be caused by a diversity of cellular events underlying replication defects that can initiate genome instability (5–4). While this explanation is hypothetical, accumulation of well characterized cases of rare tumors will potentiate identification of their molecular etiology and pathogenesis with the perspective of better diagnostics and treatment.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/geo/, GSE151766; https://www.ncbi.nlm.nih.gov/, PRJNA635906.

ETHICS STATEMENT

The patient signed informed agreement to undergo diagnostic procedures and treatment, as well as to participate in the study, and for the presentation of clinical and molecular data in scientific and medical literature.

AUTHOR CONTRIBUTIONS

KA and VS analyzed the results. KK performed the bioinformatics analysis of sequence data. KG, ES, and YC performed the clinical investigations. DP and PK performed the chromosomal microarray analysis. TP and AB performed the microscopy and immunohistochemistry. AV, DZ, and SK administered the project. All authors reviewed the manuscript.

FUNDING

The research was carried out within the state assignment of Ministry of Science and Higher Education of the Russian Federation for RCMG.

ACKNOWLEDGMENTS

Sincere thanks to Margarita Nikolaenko for assistance with manuscript preparation (translation).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01653/full#supplementary-material

REFERENCES

1. Kwon YS, Salmasi A, Han CS, Hon JD, Singer EA. Renal leiomyosarcoma: case report and review of the literature. World J Nephrol Urol. (2015) 4:213–7.
2. Ozturk H. High-grade primary renal leiomyosarcoma. Int Braz J Urol. (2015) 41:304–11. doi: 10.1590/s1677-5538.ibju.2015.02.17
3. Venkatesh K, Lamba Saini M, Niveditha SR, Krishnagiri C, Babu S. Primary leiomyosarcoma of the kidney. Patholog Res Int. (2010) 2010:652398.
4. Chudasama P, Mughal SS, Sanders MA, Hubschmann D, Chung I, Deeg KI, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. (2018) 9:144.
5. Agaram NP, Zhang L, LeRoarer F, Silik T, Sung YS, Scott SN, et al. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromos Cancer. (2016) 55:124–30. doi: 10.1002/gcc.22318
6. Lee PJ, Yoo NS, Hagemann IS, Pfeifer JD, Cottrell CE, Abel HJ, et al. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing. Exp Mol Pathol. (2017) 102:156–61. doi: 10.1016/j.yexmp.2017.01.012
7. Rao U, Schoedel KE, Petroso K, Sakai N, LaFramboise W. Genetic variants and copy number changes in soft tissue leiomyosarcoma detected by targeted amplicon sequencing. J Clin Pathol. (2019) 72:810–6. doi: 10.1136/jclinpath-2019-205998
8. Cortes-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. (2020) 52:331–41. doi: 10.1038/s41588-019-0576-7
9. van den Berg E, Molenar WM, van Echten J, Dam A, Mensink HJ, de Jong B. Cytogenetic analysis of a leiomyosarcoma of the kidney. Cancer Genet CytoGenet. (1994) 72:126–9. doi: 10.1016/0165-4604(94)90127-9
10. Siozopoulou V, Pauwels P. Pathology, genetics, and molecular biology of soft tissue tumors. In: Vanhoenacker FM, Parizel PM, Gielen JL editors. Imaging
of Soft Tissue Tumors. Cham: Springer International Publishing (2017). p. 115–30.
11. Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, et al. Multi-
factor data normalization enables the detection of copy number aberrations in
amplion sequencing data. Bioinformatics. (2014) 30:3443–50. doi: 10.1093/
biominfo/btu336
12. Zepeda-Mendoza CJ, Morton CC. The iceberg under water: unexplored
complexity of chromoanagenesis in congenital disorders. Am J Hum Genet.
(2019) 104:565–77. doi: 10.1016/j.ajhg.2019.02.024
13. Poot M. Genes, proteins, and biological pathways preventing chromothripsis. 
Methods Mol Biol (Clifton NJ). (2018) 1769:231–51. doi: 10.1007/978-1-4939-
7780-2_15
14. Marcozzi A, Pellestor F, Kloosterman WP. The genomic characteristics and
origin of chromothripsis. Methods Mol Biol (Clifton NJ). (2018) 1769:3–19. 
doi: 10.1007/978-1-4939-7780-2_1
15. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The
cBio cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer Discovery. (2012) 2:4–4. doi: 10.1158/2159-
8290.cd.12-0095
16. Liu Y, Sun J, Zhao M. ONGene: a literature-based database for human
oncogenes. J Genet Genom Yi Chuan Bao. (2017) 44:119–21. doi: 10.1016/j.
jjgg.2016.12.004
17. Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: an updated literature-
based knowledgebase for tumor suppressor genes. Nucleic Acids Res. (2016)
44:D1323–31.
18. Guilhou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. 
Virchows Arch. (2010) 456:201–17. doi: 10.1007/s00428-009-0853-4
19. George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine
leiomyosarcoma. J Clin Oncol. (2018) 36:144–50. doi: 10.1200/jco.2017.75.
9845
20. McClelland SE. Role of chromosomal instability in cancer progression. 
Endocrine Related Cancer. (2017) 24:T23–31.
21. Vargas-Rondon N, Villegas VE, Rondon-Lagos M. The role of chromosomal
instability in cancer and therapeutic responses. Cancers. (2017) 10:A4. 
doi: 10.3390/cancers10010004
22. Geijl JR, Obenauf AC, Schwarzbraun T, Speicher MR. Defining ‘chromosomal
instability’. Trends Genet TIG. (2008) 24:64–9. doi: 10.1016/j.tig.2007.11.
006
23. Yang J, Du X, Chen K, Ylipaa A, Lazar AJ, Trent J, et al. Genetic aberrations in
soft tissue leiomyosarcoma. Cancer Lett. (2009) 275:1–8. doi: 10.1016/j.
canlet.2008.06.013
24. Salawu A, Ul-Hassan A, Hammond D, Fernado M, Reed M, Sisley K. High quality genomics copy number data from archival formalin-
fixed paraffin-embedded leiomyosarcoma: optimisation of universal sirius
system labelling. PLoS One. (2012) 7:e50415. doi: 10.1371/journal.pone.005
0415
25. Sreekantiaah C, Davis JR, Sandberg AA. Chromosomal abnormalities in
leiomyosarcomas. Am J Pathol. (1993) 142:293–305.
26. Ul-Hassan A, Sisley K, Hughes D, Hammond DW, Robinson MH, Reed MW.
Common genetic changes in leiomyosarcoma and gastrointestinal stromal
tumor implication: for ataxia telangiectasia mutation involved. Int J Exp Pathol. 
(2009) 90:549–57. doi: 10.1111/j.1365-2613.2009.00680.x
27. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and
consequences of localized, complex chromosomal rearrangements. Nat Med.
(2012) 18:1630–8. doi: 10.1038/nm.2978
28. Furgason JM, Koncar RF, Michelhaugh SK, Sarkar FH, Maitland N, and
CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death
Dis. (2015) 89:918.
29. Furgason JM, Koncar RF, Michelhaugh SK, Sarkar FH, Mittal S, Sloan AE,
et al. Whole genome sequence analysis links chromothripsis to EGFR, MDM2,
MDM4, and CDK4 amplification in glioblastoma. Oncoscience. (2015) 2:618–28. 
doi: 10.18632/oncoscience.178
30. Garsed DW, Marshall OF, Corbin VD, Hsu A, Di Stefano L, Schroder J, et al. The architecture and evolution of cancer
neocromosomes. Cancer Cell. (2014) 26:653–67. doi: 10.1016/j.ccell.2014.
09.010
31. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev
Cancer. (2008) 8:523–34. doi: 10.1038/nrc2349
32. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, et al. Duplication of the MYB oncogene in
T cell acute lymphoblastic leukemia. Nat Genet. (2007) 39:593–5.
33. Clappier E, Cucuini W, Kalota A, Crinquette A, Caugya JM, Dik WA, et al. The C-MYB locus is involved in chromosomal translocation and
genomic duplications in human T-cell acute leukemia (T-ALL), the translocation
defining a new T-ALL subtype in very young children. Blood. (2007) 110:1251–
61. doi: 10.1182/blood-2006-12-64683
34. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O,
et al. MYB oncogene amplification in hereditary BRCAl breast cancer. Cancer
Res. (2000) 60:5323–8.
51. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. *Nat Med.* (2009) 15:59–67. doi: 10.1038/nm.1889

52. Wu Z, Zhou R, Su Y, Sun L, Liao Y, Liao W. Prognostic value of MACC1 in digestive system neoplasms: a systematic review and meta-analysis. *BioMed Res Int.* (2015) 2015:252043.

53. Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. *Nat Med.* (2011) 17:944–51. doi: 10.1038/nm.2392

54. Aguilera A, Gomez-Gonzalez B. Genome instability: a mechanistic view of its causes and consequences. *Nat Rev Genet.* (2008) 9:204–17. doi: 10.1038/nrg2268

**Conflict of Interest:** DP and PK were employed by the company Genomed Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Anoshkin, Karandasheva, Goryacheva, Pyankov, Koshkin, Pavlova, Bobin, Slapot, Chernov, Vinarov, Zaletaev, Kutsev and Strelnikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.